Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382954 · ClinicalTrials.gov registry record · Phase 1
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
A Phase 1 study, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00382954 is a Phase 1 study that has completed, run by University of Kentucky. The registered enrollment target is 55 participants.
The verdict
NCT00382954, a Phase 1 study, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients \>60 years or relapsed AML patients. Another purpose of this study is to determine the dose limiting toxicities associated with bortezomib in combination with idarubicin in newly diagnosed AML patients \>60 years or relapsed AML patients.
Interventions
- DRUG Idarubicin
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382954
The ClinicalTrials.gov registry entry for NCT00382954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Idarubicin is the first listed.
NCT00382954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00382954 about?
NCT00382954 is a clinical study titled "Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML". The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients \>60 years or relapsed AML patients. Another purpose of this study is to determine the dose limiting toxicities associated with bortezomib in ...
What is the current status of trial NCT00382954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2004-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00382954?
The interventions under investigation include: Idarubicin (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00382954?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.